Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 52 (2) , 247-253
- https://doi.org/10.1016/j.jaad.2004.08.046
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infantsThe Journal of Pediatrics, 2003
- The Benefit of Pimecrolimus (Elidel, SDZ ASM 981) on Parents’ Quality of Life in the Treatment of Pediatric Atopic DermatitisPublished by American Academy of Pediatrics (AAP) ,2002
- Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drugJournal of Allergy and Clinical Immunology, 2002
- Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in ChildrenPediatrics, 2002
- Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsJournal of the American Academy of Dermatology, 2002
- Topical PimecrolimusDrugs, 2002
- Pimecrolimus (Elidel, SDZ ASM 981)—Preclinical pharmacologic profile and skin selectivitySeminars in Cutaneous Medicine and Surgery, 2001
- First experience of topical SDZ ASM 981 in children with atopic dermatitisBritish Journal of Dermatology, 2001
- A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyBritish Journal of Dermatology, 1999
- A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:in vivopharmacologyBritish Journal of Dermatology, 1997